Expression of tissue inhibitor of matrix metalloproteinases (TIMP)-3 protein in invasive breast carcinoma: Relation to tumor phenotype and clinical outcome

Breast Cancer Research

Volumn 8, Issue 5, 2006, Pages

  Mylona, Eleni ^a   Magkou, Christina ^b   Giannopoulou, Ioanna ^a   Agrogiannis, George ^a   Markaki, Sofia ^c   Keramopoulos, Antonios ^c   Nakopoulou, Lydia ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c ALEXANDRA HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE (ATP HYDROLYSING) ALPHA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MUTANT PROTEIN; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR MARKER; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER SURVIVAL; CARCINOMA IN SITU; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PHENOTYPIC VARIATION; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STROMA; BIOSYNTHESIS; BREAST TUMOR; GENETICS; METABOLISM; MIDDLE AGED; PHENOTYPE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FEMALE; HUMANS; MIDDLE AGED; PHENOTYPE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33750688149     PISSN: 1465542X     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1607     Document Type: Article

References (37)

1. Freije J, Balbin M, Pendas AM, Sanchez LM, Puente XS, Lopez-Otin C: Matrix metalloproteinases and tumor progression. Adv Exp Med Biol 2003, 532:91-107.
2. Fassina G, Ferrari N, Brigati C, Benelli R, Santi L, Noonan DM, Albini A: Tissue inhibitors of metalloproteases: regulation and biological activities. Clin Exp Metastasis 2000, 18:111-120.
3. Jiang Y, Goldberg ID, Shi YE: Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002, 21:2245-2252.
4. Yu WH, Yu S, Meng Q, Brew K, Woessner JF Jr: TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix. J Biol Chem 2000, 275:31226-31232.
5. 1 progression, mitogenic stimulation, differentiation and senescence. J Biol Chem 1994, 269:18953-18960.
6. Loging WT, Reisman D: Inhibition of the putative tumor suppressor gene TIMP-3 by tumor-derived p53 mutants and wild type p53. Oncogene 1999, 18:7608-7615.
7. Baker AH, Zaltsman AB, George SJ, Newby AC: Divergent effects of tissue inhibitor of metalloproteinase-1, -2 or -3 over-expression on rat vascular smooth muscle cell invasion, proliferation and death in vitro. J Clin Invest 1998, 101:1478-1487.
8. Ahonen M, Baker AH, Kahari VM: Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res 1998, 58:2310-2315.
9. Baker AH, George SJ, Zaltsman AB, Murphy G, Newby AC: Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br J Cancer 1999, 79:1347-1355.
10. Yang TT, Hawkes SP: Role of the 21-kDa protein TIMP-3 in oncogenic transformation of cultured chicken embryo fibroblasts. Proc Natl Acad Sci USA 1992, 89:10676-10680.
11. Bian J, Wang Y, Smith MR, Kim H, Jacobs C, Jackman J, Kung HF, Colburn NH, Sun Y: Characterization of a putative p53 binding site in the promoter of the mouse inhibitor of metalloproteinases-3 (TIMP-3) gene: TIMP-3 is not a p53 target gene. Carcinogenesis 1996, 17:1805-1811.
12. Bond M, Murphy G, Bennett MR, Newby AC, Baker AH: Tissue inhibitor of metalloproteinase-3 induces a Fas-associated death domain-dependent type II apoptotic pathway. J Biol Chem 2002, 277:13787-13795.
13. Smith MR, Kung H, Durum SK, Colburn NH, Sun Y: TIMP-3 induces cell death by stabilizing TNF-α receptors on the surface of human colon carcinoma cells. Cytokine 1997, 9:770-780.
14. Leco KJ, Waterhouse P, Sanchez OH, Gowing KL, Poole AR, Wakeham A, Mak TW, Khokha R: Spontaneous air space enlargement in the lungs of mice lacking tissue inhibitor of metalloproteinases-3 (TIMP-3). J Clin Invest 2001, 108:817-829.
15. Ahonen M, Ala-Aho R, Baker AH, George SI, Gernman R, Saarialho-Kere U, Kahari VM: Antitumor activity and bystander effect of adenovirally delivered tissue inhibitor of metalloproteinases-3. Mol Ther 2002, 5:705-715.
16. Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, Cavenee WK, Baylin SB, Graff JR: Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggests a suppressor role in kidney, brain and other human cancers. Cancer Res 1999, 59:798-802.
17. Darnton SJ, Hardie LJ, Muc RS, Wild CP, Casson AG: Tissue inhibitor of metalloproteinase-3 (TIMP-3) gene is methylated in the development of esophageal adenocarcinoma: loss of expression correlates with poor prognosis. Int J Cancer 2005, 115:351-358.
18. Miyazaki T, Kato H, Nakajima M, Faried A, Takita J, Sohda M, Fukai Y, Yamaguchi S, Masuda N, Manda R, et al.: An immunohistochemical study of TIMP-3 expression in oesophageal squamous cell carcinoma. Br J Cancer 2004, 91:1556-1560.
19. Curran S, Dundas SR, Buxton J, Leeman MF, Ramsay R, Murray IG: Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res 2004, 10:8229-8234.
20. Tunuguntla R, Ripley D, Sang QX, Chegini N: Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinases TIMP-3 and -4 in benign endometrium and endometrial cancer. Gynecol Oncol 2003, 89:453-459.
21. Karan D, Lin FC, Bryan M, Ringel J, Moniaux N, Lin MF, Batra SK: Expression of ADAMs (a disintegrin and metalloproteases) and TIMP-3 (tissue inhibitor of metalloproteinase-3) in human prostatic adenocarcinoma. Int J Oncol 2003, 23:1365-1371.
22. Byrne JA, Tomasetto C, Rouyer N, Bellocq JP, Rio MC, Basset P: The tissue inhibitor of metalloproteinases-3 gene in breast carcinoma: identification of multiple polyadenylation sites and stromal pattern of expression. Mol Med 1995, 1:418-427.
23. Span PN, Lindberg R, Manders P, Tjan-Heijnen VC, Heuvel JJ, Beex LV, Sweep CG: Tissue inhibitor of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success. J Pathol 2004, 202:395-402.
24. Kotzsch M, Farthmann J, Meye A, Fuessel S, Baretton G, Tjan-Heijnen VC, Schmitt M, Luther T, Sweep FC, Magdolen V, et al.: Prognostic relevance of uPAR-del4/5 and TIMP-3 mRNA expression levels in breast cancer. Eur J Cancer 2005, 41:2760-2768.
25. Tavassoéli FA, Devilee P: Pathology and Genetics: Tumors of the Breast and Female Genital Organs Lyon: WHO Press; 2003. IARC WHO Classification of Tumours, No. 4.
26. Robins P, Pinder S, de Klerk N: Histological grading of breast carcinomas: a study of interobserver agreement. Human Pathol 1995, 6:873-879.
27. Union International Contre Cancer: TNM Classification of International Union against Cancer. In TNM Atlas, 3rd revision 4th edition. Edited by: Hermanek P, Sabin H. Berlin: Springer-Verlag; 1992:15-25.
28. Laskawi NH, Wahlers A, Hemmerlein B: Expression of matrix metalloproteinases MMP-2, MMP-9 and tissue inhibitors TIMP-1, -2, and -3 in benign and malignant tumours of the salivary gland. Histopathology 2004, 44:222-231.
29. McCleilland RA, Wilson D, Leake R, Finlay P, Nicholson RI: A multicentre study into the reliability of steroid receptor immunocytochemical assay quantification. Eur J Cancer 1991, 27:711-716.
30. Nakopoulou L, Lazaris AC, Kavantzas N, Alexandrou P, Athanassiadou P, Keramopoulos A, Davaris P: DNA topoisomerase II-α immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer. Pathobiology 2000, 68:137-143.
31. Nakopoulou L, Stefanaki K, Panayotopoulou E, Giannopoulou I, Athanassiadou P, Gakiopoulou-Givalou H, Louvrou A: Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation. Hum Pathol 2002, 33:863-870.
32. Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature 2000, 408:307-310.
33. Vousden KH, Prives C: p53 and prognosis: new insights and further complexity. Cell 2005, 120:7-10.
34. Lynch BJ, Guinee DG Jr, Holden JA: Human DNA topoisomerase II-α: a new marker of cell proliferation in invasive breast cancer. Hum Pathol 1997, 28:1180-1188.
35. Adams JM, Cory S: Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci 2001, 26:61-66.
36. Nothnick WB, Zhang X, Zhou HE: Steroidal regulation of uterine edema and tissue inhibitors of metalloproteinase (TIMP)-3 messenger RNA expression is altered in TIMP-1 deficient mice. Biol Reprod 2004, 70:500-508.
37. Fata JE, Chaudhary V, Khokha R: Cellular turnover in the mammary gland is corrected with systemic levels of progesterone and not 17β-estradiol during the estrous cycle. Biol Reprod 2001, 65:680-688.